论文部分内容阅读
目的评价米卡芬净治疗血液肿瘤患者侵袭性真菌感染(IFI)的疗效及安全性。方法对同期收治的38例恶性血液病并发IFI患者应用米卡芬净治疗,观察疗效及安全性。结果38例总有效率为57.9%(22/38),确诊、临床诊断与拟诊者有效率分别为75.0%、63.2%、36.4%;38例均未出现临床和实验室不良反应。结论米卡芬净抗菌谱广,临床疗效及安全性好,可作为恶性血液病患者预防、经验性和抢先抗真菌治疗的药物。
Objective To evaluate the efficacy and safety of micafungin in the treatment of invasive fungal infection (IFI) in patients with hematological malignancies. Methods 38 patients with malignant hematological disease complicated with IFI were treated with micafungin, and the efficacy and safety were observed. Results The total effective rate in 38 cases was 57.9% (22/38). The effective rates of diagnosis, clinical diagnosis and diagnosis were 75.0%, 63.2% and 36.4% respectively. No clinical or laboratory adverse reactions were observed in 38 cases. Conclusion Micafungin net antimicrobial spectrum, clinical efficacy and safety, and can be used as a preventive, empirical and preemptive antifungal therapy in patients with hematologic malignancies.